Zenas BioPharma Stock Slips as a June Catalyst Moves Into View
Zenas BioPharma shares ended lower on Tuesday, lagging a firmer biotech tape as investors looked past the long U.S. market weekend and toward a June presentation for its lead autoimmune drug. The Nasdaq-listed stock was quoted at $18.73, down about 1.3%, after trading between $18.61 and $19.27. Its 52-week range runs from $8.91 to $44.60, underscoring how much trial news still drives the name.